Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 7/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | GCK | P35557 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15574419 | 0.90 | DDR2 (0.53) | P2RX3METHDAC1HDAC6GSK3B | |
| SCHEMBL16990603 | 0.89 | HDAC1 (0.59) | P2RX3HDAC1HDAC6GSK3BSMN1; SMN2 | |
| SCHEMBL16990725 | 0.88 | DDR2 (0.56) | P2RX3METHDAC1HDAC6L3MBTL1 | |
| SCHEMBL15573219 | 0.85 | GRM5 (0.52) | METHDAC1HDAC6GSK3BSMN1; SMN2 | |
| SCHEMBL16990654 | 0.85 | HDAC1 (0.55) | P2RX3HDAC1HDAC6GSK3BSMN1; SMN2 | |
| SCHEMBL15574905 | 0.84 | GCK (0.47) | METGSK3BGCK | |
| SCHEMBL15575329 | 0.82 | KMT2A (0.60) | P2RX3SMN1; SMN2L3MBTL1POLBDDR2 | |
| SCHEMBL15574560 | 0.82 | NPC1 (0.58) | SMN1; SMN2MAPK14POLB | |
| SCHEMBL16990706 | 0.81 | RAF1 (0.62) | MAPK14 | |
| SCHEMBL15573350 | 0.80 | P2RX3 (0.44) | P2RX3DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | P2RX3 540/4885MET 863/4885HDAC1 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.